Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation.

Article English OPEN
Baron, Frédéric; Sautois, Brieuc; Baudoux, Etienne; Matus, Geoffrey; Fillet, Georges; Beguin, Yves;
  • Subject: Adolescent | Adult | Anemia, Aplastic/therapy | Bone Marrow Transplantation | Child | Cyclosporine/therapeutic use | Drug Administration Schedule | Erythropoietin, Recombinant/administration & dosage/therapeutic use | Female | Graft vs Host Disease/epidemiology | Hematopoietic Stem Cell Transplantation | Humans | Immunosuppressive Agents/therapeutic use | Leukemia/therapy | Lymphoma, Non-Hodgkin/therapy | Male | Middle Aged | Myelodysplastic Syndromes/therapy | Thrombocytosis/therapy | Transplantation, Homologous/physiology | : Hematology [Human health sciences] | : Hématologie [Sciences de la santé humaine]

OBJECTIVE: Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with prolonged anemia caused by defective erythropoietin (Epo) production. We enrolled 34 recipients of an allogeneic HSCT in three consecutive trials to determine the optimal utilization... View more
Share - Bookmark